论文部分内容阅读
目的 观察干扰素α2 b和病毒唑联合疗法与单用干扰素α2 b治疗慢性丙型肝炎的生化、病毒学应答以及使用安全性评估。方法 慢性丙型肝炎患者 5 0例 ,随机双盲分为干扰素α2 b(3MU,每周 3次 )和病毒唑 (1 0 5 0 m g/ d)联合治疗组与单用干扰素α2 b治疗组。疗程 2 4周 ,停药后再随访 2 4周 ,在治疗 2 4周、随访 2 4周时不能测得 HCV RNA为病毒学立即和持续应答。结果 治疗结束时联合治疗组 2 3例 (76 .6 7% )达到病毒学应答 ,而对照组仅 9例 (45 .0 0 % ,P<0 .0 5 )。在随访期联合治疗组病毒学持续应答率也较对照组高 (P<0 .0 5 )。联合疗法也可用于以往曾单用干扰素无效的病人 ,并取得较好的疗效。结论 干扰素α2 b和病毒唑联合治疗慢性丙型肝炎较单用干扰素α2 b具有较高的病毒学应答。
Objective To observe the biochemical and virological response of interferon α 2b and ribavirin combination therapy and interferon α 2b alone in the treatment of chronic hepatitis C, and to evaluate the safety of its use. Methods Fifty patients with chronic hepatitis C were randomly divided into interferon α2b (3MU, three times a week) and ribavirin (105 mg / d) combined with interferon α2b group. After 24 weeks of treatment and 24 weeks after discontinuation, HCV RNA was not detected as virological immediate and sustained response at 24 weeks of treatment and at 24 weeks of follow-up. Results Twenty-three (76.67%) patients in the combined treatment group achieved virologic response by the end of the treatment period, compared with 9 in the control group (45.0%, P <0.05). The follow-up period of combination therapy group virological response rate was also higher than the control group (P <0.05). Combination therapy can also be used in the past who had interferon alone invalid patients, and achieved better results. Conclusion The combination of interferon α 2b and ribavirin has a higher virological response to chronic hepatitis C than interferon α 2b alone.